Volume | 15,069 |
|
|||||
News | - | ||||||
Day High | 1.89 | Low High |
|||||
Day Low | 1.5801 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eterna Therapeutics Inc | ERNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.73 | 1.5801 | 1.89 | 1.7899 | 1.7357 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
107 | 15,069 | $ 1.76 | $ 26,539 | - | 0.840101 - 3.45 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:29:02 | 8 | $ 1.77 | USD |
Eterna Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
9.68M | 5.41M | - | 68k | -21.68M | -4.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Eterna Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ERNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.05 | 2.2361 | 1.5801 | 1.91 | 7,264 | -0.2601 | -12.69% |
1 Month | 2.47 | 2.50 | 1.5801 | 2.10 | 4,665 | -0.6801 | -27.53% |
3 Months | 1.78 | 2.57 | 1.43 | 2.00 | 8,478 | 0.0099 | 0.56% |
6 Months | 1.48 | 2.57 | 0.840101 | 1.51 | 21,927 | 0.3099 | 20.94% |
1 Year | 3.00 | 3.45 | 0.840101 | 1.91 | 20,459 | -1.21 | -40.34% |
3 Years | 4.20 | 7.15 | 0.840101 | 3.78 | 38,571 | -2.41 | -57.38% |
5 Years | 4.20 | 7.15 | 0.840101 | 3.78 | 38,571 | -2.41 | -57.38% |
Eterna Therapeutics Description
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using advanced cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs. |